ArticleViruses2023
SARS-CoV-2 Disease Severity in the Golden Syrian Hamster Model of Infection Is Related to the Volume of Intranasal Inoculum.
Abstract read
In one paragraph
Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- A multimodaliScience · 2026Article
- Virobiome-mediated regulation of microbiota-gut-brain axis signaling and neuroimmune homeostasis.Cell communication and signaling : CCS · 2026Review
- Article
- Therapeutic Efficacy of Indole-3-Carbinol Against SARS-CoV-2-Induced Acute Respiratory Distress Syndrome: A Dual Antiviral and Anti-Inflammatory Approach in a Golden Syrian Hamster Model.Journal of cellular and molecular medicine · 2026Article
- Extra gene coding capacity of SARS-CoV-2 provides a virus engineering platform for in vitro and in vivo applications.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Translational insights into Long-COVID: evaluation of preclinical animal models along the lung-brain-immune axis with focus on Golden Syrian Hamsters.Journal of neuroinflammation · 2026Review
- Article
- Identification of immunodominant T cell epitopes in SARS-CoV-2 spike protein in Syrian hamsters.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Pathomorphological Features of Lung Damage Caused by Infection with Various Variants of SARS-CoV-2 in Humanized Model Animals.Doklady. Biochemistry and biophysics · 2026Article
- Current Advances and Applications of Animal Models in SARS-CoV-2 Pathogenesis and Vaccine Development.Microorganisms · 2025Review
- Pathology and host-pathogen interactions in a golden Syrian hamster model of Nipah virus infection.Frontiers in veterinary science · 2025Article
- Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.Journal of virology · 2024Article
- Uncovering the Contrasts and Connections in PASC: Viral Load and Cytokine Signatures in Acute COVID-19 versus Post-Acute Sequelae of SARS-CoV-2 (PASC).Biomedicines · 2024Review
- Single-cell analysis of VACV infection reveals pathogen-driven timing of early and late phases and host-limited dynamics of virus production.PLoS pathogens · 2024Article
- Immunobiology of COVID-19: Mechanistic and therapeutic insights from animal models.Zoological research · 2024Review
- Characterization of a SARS-CoV-2 Omicron BA.5 direct-contact transmission model in hamsters.Npj viruses · 2024Article
- Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in a COVID-19 hamster model.EBioMedicine · 2024Article
- Cardiomyopathy Does Not Exacerbate the Severity of Pneumonia Caused by a SARS-CoV-2 Delta Variant in the J2N-k Hamster Model.Viruses · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Alastair HandleyUKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK.
Kathryn A RyanUKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK.ORCID 0000-0001-8608-1144
Elizabeth R DaviesUKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK.ORCID 0000-0002-8629-8324
Kevin R BewleyUKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK.ORCID 0000-0002-9078-6734
Oliver T CarnellUKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK.ORCID 0000-0001-8847-5489
Amy ChallisUKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK.ORCID 0000-0002-4835-2211
Naomi S CoombesUKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK.ORCID 0000-0001-9631-6875
Susan A FotheringhamUKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK.
Karen E GoochUKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK.
Michael CharltonUKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK.
Debbie J HarrisUKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK.
Chelsea KennardUKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK.
Didier NgaboUKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK.ORCID 0000-0003-1818-1439
Thomas M WeldonUKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK.ORCID 0000-0002-2431-304X
Francisco J SalgueroUKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK.ORCID 0000-0002-5315-3882
Simon G P FunnellUKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK.
Yper HallUKHSA Porton, Vaccine Development and Evaluation Centre, UK Health Security Agency, Manor Farm Road, Salisbury SP4 0JG, UK.
Funding
World Health Organization 001
Abstract
The golden Syrian hamster (
Indexed as
COVID-19AnimalsCricetinaeDisease Models, AnimalHumansLungMesocricetusPatient AcuitySARS-CoV-2animal modelcoronavirusSARS-CoV-2Syrian hamster
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.